Welcome!

News Feed Item

PharmaPoint: Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis to 2022

NEW YORK, June 26, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01364262/PharmaPoint-Hepatitis-C-Virus---United-Kingdom-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

PharmaPoint: Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, "PharmaPoint: Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis to 2022". Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche's Pegasys and Merck's PegIntron) and ribavirin (e.g., Roche's Copegus and Merck's Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck's Victrelis (boceprevir) or Vertex's Incivek (telaprevir). The entrance of next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm. GlobalData expects a dramatic shift favoring the uptake of interferon-free regimens due to their more tolerable side-effect profiles and decreased duration of therapy compared with the current standard of care.

The anticipated drivers of growth in the UK market included increased awareness of HCV, the launch of improved HCV regimens, and advocacy for access to next-generation therapies.

Janssen's Incivo is the current market leader in the UK. Incivo was among the first DAA HCV therapies launched in the UK. The regimen had an improved efficacy compared with the previous standard of care for HCV GT1, a combination of peginterferon and ribavirin. GlobalData assumes that Incivo's shorter duration of triple-therapy (i.e., DAA, peginterferon, and ribavirin) compared with Merck's Victrelis enabled it to outcompete Victrelis for market share. Incivo and Victrelis are both associated with adverse events, which has resulted in HCV-infected patients in the UK deciding to forego therapy in order to await the launch of more-tolerable HCV therapies.

Scope

- Overview of the HCV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the UK from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the UK HCV market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HCV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the UK

Table of Contents

1 Table of CContents 4
1.1 List of Tables 7
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 16
3.1.3 Prognosis 17
3.2 Symptoms 17
4 Disease Management 18
4.1 Diagnosis and Referral Overview 18
4.2 Treatment Overview 19
4.3 UK 22
4.3.1 Diagnosis 22
4.3.2 Clinical Practice 23
5 Competitive Assessment 24
5.1 Overview 24
5.2 Strategic Competitor Assessment 24
5.3 Product Profiles – Major Brands 26
5.3.1 Incivek (telaprevir) 26
5.3.2 Victrelis (boceprevir) 31
5.3.3 Pegasys (peginterferon alfa-2a) 36
5.3.4 PegIntron (peginterferon alfa-2b) 41
5.3.5 Copegus, Rebetol, and Generic Ribavirin 45
5.3.6 Therapeutic Class: Interferon 48
6 Opportunity and Unmet Need 49
6.1 Overview 49
6.2 Unmet Needs 50
6.2.1 Unmet Need: Treatment Tolerability 50
6.2.2 Unmet Need: Efficacy 50
6.2.3 Unmet Need: Disease Awareness 51
6.2.4 Unmet Need: Treatment Cost 52
6.2.5 Unmet Need: Shorter Treatment Duration 52
6.2.6 Unmet Need: Simplified Treatment Regimens 53
6.3 Unmet Needs Gap Analysis 54
6.4 Opportunities 55
6.4.1 Opportunity: Pan-genotypic HCV Regimen 55
6.4.2 Opportunity: Treatment of Underrepresented Patient Populations 55
6.4.3 Opportunity: Involvement of Immune System 56
7 Pipeline Assessment 57
7.1 Overview 57
7.2 Promising Drugs in Clinical Development 58
7.2.1 Sofosbuvir and Sofosbuvir/Ledipasvir 60
7.2.2 Simeprevir 70
7.2.3 ABT-450 plus ABT-267 and ABT-333 78
7.2.4 Faldaprevir and Faldaprevir plus BI 207127 85
7.2.5 Daclatasvir and Daclatasvir plus Asunaprevir 93
7.2.6 Other Drug Classes 101
8 Market Outlook 104
8.1 UK 104
8.1.1 Forecast 104
8.1.2 Key Events 109
8.1.3 Drivers and Barriers 109
9 Appendix 112
9.1 Bibliography 112
9.2 Abbreviations 120
9.3 Methodology 121
9.4 Forecasting Methodology 121
9.4.1 Percent Drug-Treated Patients 121
9.4.2 Patient Warehousing 122
9.4.3 Drugs Included in Each Therapeutic Class 122
9.4.4 Launch and Patent Expiry Dates 123
9.4.5 General Pricing Assumptions 124
9.4.6 Individual Drug Assumptions 124
9.4.7 Generic Erosion 126
9.4.8 Selection of Pipeline Agents 126
9.4.9 Pricing of Pipeline Agents 127
9.5 Physicians and Specialists Included in this Study 130
9.6 Survey of Prescribing Physicians 132
9.7 About the Authors 133
9.7.1 Author 133
9.7.2 Global Head of Healthcare 133
9.8 About GlobalData 134
9.9 Contact Us 134
9.10 Disclaimer 134

List of Tables

Table 1: Modes of HCV Transmission 16
Table 2: Symptoms of Acute and Chronic HCV Infection 17
Table 3: HCV Genotypes Present in the 9MM 19
Table 4: General Standard of Care by HCV Genotype 19
Table 5: Treatment Guidelines for HCV by Country 21
Table 6: Most-Prescribed Drugs for HCV by Class in the Global Markets, 2013 21
Table 7: Leading Treatments for HCV, 2012 25
Table 8: Product Profile – Incivek 27
Table 9: Efficacy of Incivek in Treatment-Naïve Patients (ADVANCE Trial) 27
Table 10: Efficacy of Incivek in Treatment-Experienced Patients (REALIZE Trial) 28
Table 11: Common Incivek Adverse Drug Reactions 29
Table 12: Incivek SWOT Analysis, 2012 30
Table 13: Product Profile – Victrelis 31
Table 14: Victrelis Efficacy in Treatment-Naïve Patients (SPRINT-2 Trial) 32
Table 15: Victrelis Efficacy in Treatment-Experienced Patients (RESPOND-2 Trial) 33
Table 16: Victrelis SWOT Analysis, 2012 35
Table 17: Product Profile – Pegasys 37
Table 18: Antiviral Efficacy of Peginterferon alfa-2a Compared with Interferon alfa-2b 38
Table 19: Pegasys SWOT Analysis, 2012 40
Table 20: Product Profile – PegIntron 42
Table 21: Antiviral Efficacy of Peginterferon alfa-2b Compared with Interferon alfa-2b 42
Table 22: PegIntron SWOT Analysis, 2012 44
Table 23: Effect of Addition of Ribavirin to Peginterferon HCV Therapy 46
Table 24: Ribavirin SWOT Analysis, 2012 47
Table 25: Summary of Minor Therapeutic Classes, 2012 48
Table 26: Overall Unmet Needs – Current Level of Attainment 49
Table 27: Clinical Unmet Needs – Gap Analysis, 2012 54
Table 28: HCV – Pipeline, 2012 58
Table 29: Comparison of Therapeutic Classes in Development for HCV, 2012 59
Table 30: Gilead's Sofosbuvir Ongoing Clinical Trials of Interest 61
Table 31: Product Profile – Sofosbuvir 62
Table 32: Sofosbuvir's Most Common Adverse Effects 65
Table 33: Sofosbuvir SWOT Analysis, 2012 69
Table 34: Janssen's Simeprevir Ongoing Clinical Trials of Interest 71
Table 35: Product Profile – Simeprevir 72
Table 36: PILLAR Clinical Trial Results 72
Table 37: Adverse Events Observed in PILLAR Clinical Trial 73
Table 38: Simeprevir SWOT Analysis, 2012 77
Table 39: AbbVie's Combination Therapy Ongoing Clinical Trials of Interest 79
Table 40: Product Profile – AbbVie Combination Therapy 80
Table 41: AVIATOR Clinical Trial Results 80
Table 42: AbbVie Combination Therapy SWOT Analysis, 2012 84
Table 43: Boehringer Ingelheim's Faldaprevir Ongoing Clinical Trials of Interest 86
Table 44: Product Profile – Faldaprevir 87
Table 45: Efficacy of Interferon-Free Faldaprevir Regimen (SOUND-C2 Trial) 87
Table 46: Faldaprevir SWOT Analysis, 2012 92
Table 47: Bristol-Myers Squibb's Daclatasvir Ongoing Clinical Trials of Interest 94
Table 48: Product Profile – Daclatasvir 95
Table 49: Efficacy of Daclatasvir in Treatment-Naïve Patients (COMMAND-1 Trial) 95
Table 50: Daclatasvir and Asunaprevir Quad Therapy Efficacy 96
Table 51: Daclatasvir Triple Therapy Adverse Events 97
Table 52: Daclatasvir SWOT Analysis, 2012 100
Table 53: Comparison of Peginterferon lambda with Peginterferon alfa (EMERGE Trial) 101
Table 54: Efficacy of Alisporivir in Treatment-Naïve HCV GT2/3 Patients (VITAL-1 Trial) 102
Table 55: Sales Forecasts ($m) for HCV in the UK, 2012–2022 107
Table 56: Key Events Impacting Sales for HCV in the UK, 2012 109
Table 57: UK HCV Market – Drivers and Barriers, 2012 109
Table 58: Key Launch Dates 123
Table 59: Key Patent Expiries 123
Table 60: Physicians Surveyed, By Country 132

List of Figures

Figure 1: HCV Genome and Polyprotein Composition 13
Figure 2: HCV Lifecycle Overview 14
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in HCV, 2012–2022 58
Figure 4: Sales for HCV Therapeutics in the UK by Drug Class, 2012–2022 108

To order this report:
Drug_and_Medication Industry:
PharmaPoint: Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis to 2022

__________________________
Contact Clare: [email protected]  
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
IoT solutions exploit operational data generated by Internet-connected smart “things” for the purpose of gaining operational insight and producing “better outcomes” (for example, create new business models, eliminate unscheduled maintenance, etc.). The explosive proliferation of IoT solutions will result in an exponential growth in the volume of IoT data, precipitating significant Information Governance issues: who owns the IoT data, what are the rights/duties of IoT solutions adopters towards t...
Get deep visibility into the performance of your databases and expert advice for performance optimization and tuning. You can't get application performance without database performance. Give everyone on the team a comprehensive view of how every aspect of the system affects performance across SQL database operations, host server and OS, virtualization resources and storage I/O. Quickly find bottlenecks and troubleshoot complex problems.
Whether your IoT service is connecting cars, homes, appliances, wearable, cameras or other devices, one question hangs in the balance – how do you actually make money from this service? The ability to turn your IoT service into profit requires the ability to create a monetization strategy that is flexible, scalable and working for you in real-time. It must be a transparent, smoothly implemented strategy that all stakeholders – from customers to the board – will be able to understand and comprehe...
Between 2005 and 2020, data volumes will grow by a factor of 300 – enough data to stack CDs from the earth to the moon 162 times. This has come to be known as the ‘big data’ phenomenon. Unfortunately, traditional approaches to handling, storing and analyzing data aren’t adequate at this scale: they’re too costly, slow and physically cumbersome to keep up. Fortunately, in response a new breed of technology has emerged that is cheaper, faster and more scalable. Yet, in meeting these new needs they...
Complete Internet of Things (IoT) embedded device security is not just about the device but involves the entire product’s identity, data and control integrity, and services traversing the cloud. A device can no longer be looked at as an island; it is a part of a system. In fact, given the cross-domain interactions enabled by IoT it could be a part of many systems. Also, depending on where the device is deployed, for example, in the office building versus a factory floor or oil field, security ha...
An IoT product’s log files speak volumes about what’s happening with your products in the field, pinpointing current and potential issues, and enabling you to predict failures and save millions of dollars in inventory. But until recently, no one knew how to listen. In his session at @ThingsExpo, Dan Gettens, Chief Research Officer at OnProcess, discussed recent research by Massachusetts Institute of Technology and OnProcess Technology, where MIT created a new, breakthrough analytics model for s...
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busin...
"We are the public cloud providers. We are currently providing 50% of the resources they need for doing e-commerce business in China and we are hosting about 60% of mobile gaming in China," explained Yi Zheng, CPO and VP of Engineering at CDS Global Cloud, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
"We are a custom software development, engineering firm. We specialize in cloud applications from helping customers that have on-premise applications migrating to the cloud, to helping customers design brand new apps in the cloud. And we specialize in mobile apps," explained Peter Di Stefano, Vice President of Marketing at Impiger Technologies, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lead...
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
Video experiences should be unique and exciting! But that doesn’t mean you need to patch all the pieces yourself. Users demand rich and engaging experiences and new ways to connect with you. But creating robust video applications at scale can be complicated, time-consuming and expensive. In his session at @ThingsExpo, Zohar Babin, Vice President of Platform, Ecosystem and Community at Kaltura, discussed how VPaaS enables you to move fast, creating scalable video experiences that reach your aud...